Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1989 Oct;121(4):603-8.
doi: 10.1530/acta.0.1210603.

Serum GH binding protein activities identifies the heterozygous carriers for Laron type dwarfism

Affiliations

Serum GH binding protein activities identifies the heterozygous carriers for Laron type dwarfism

Z Laron et al. Acta Endocrinol (Copenh). 1989 Oct.

Abstract

Measurement of GH-binding protein activity and IGF-I was carried out in the sera of 13 patients with Laron type dwarfism, a syndrome caused by a lack of GH receptors which leads to impairment of IGF-I generation, and those of 16 of their close relatives. GH binding protein activity was measured by incubating 125I-hGH with 100 microliters serum in the presence and in the absence of excess unlabelled hGH, followed by separation of specifically bound 125I-hGH binding protein complexes from free 125I-hGH by gel filtration. The results are expressed as percent specific binding relative to an adult reference serum. IGF-I was determined by RIA after acid extraction on octadecylsilane silica columns. All Laron type dwarfism patients had no, or only negligible GH binding protein activity, which supports the evidence that serum GH binding protein corresponds to the extracellular domain of the membranal GH receptor. Eight of the 16 relatives had serum GH binding protein activity more than 2 SD below the mean for age, a finding considered to denote heterozygocity for their molecular defect disease. The significant correlation (p less than 0.001) between serum GH binding protein activity and IGF-I levels supports this conclusion. The ability to define heterozygotes of Laron type dwarfism will be helpful in genetic counselling.

PubMed Disclaimer

Similar articles

Cited by

  • Height-reducing variants and selection for short stature in Sardinia.
    Zoledziewska M, Sidore C, Chiang CWK, Sanna S, Mulas A, Steri M, Busonero F, Marcus JH, Marongiu M, Maschio A, Ortega Del Vecchyo D, Floris M, Meloni A, Delitala A, Concas MP, Murgia F, Biino G, Vaccargiu S, Nagaraja R, Lohmueller KE; UK10K consortium; Timpson NJ, Soranzo N, Tachmazidou I, Dedoussis G, Zeggini E; Understanding Society Scientific Group; Uzzau S, Jones C, Lyons R, Angius A, Abecasis GR, Novembre J, Schlessinger D, Cucca F. Zoledziewska M, et al. Nat Genet. 2015 Nov;47(11):1352-1356. doi: 10.1038/ng.3403. Epub 2015 Sep 14. Nat Genet. 2015. PMID: 26366551 Free PMC article.
  • Nonclassical GH Insensitivity: Characterization of Mild Abnormalities of GH Action.
    Storr HL, Chatterjee S, Metherell LA, Foley C, Rosenfeld RG, Backeljauw PF, Dauber A, Savage MO, Hwa V. Storr HL, et al. Endocr Rev. 2019 Apr 1;40(2):476-505. doi: 10.1210/er.2018-00146. Endocr Rev. 2019. PMID: 30265312 Free PMC article. Review.
  • An update on Laron syndrome.
    Laron Z. Laron Z. Arch Dis Child. 1993 Mar;68(3):345-6. doi: 10.1136/adc.68.3.345. Arch Dis Child. 1993. PMID: 8466235 Free PMC article. No abstract available.
  • Screening tests for growth hormone deficiency.
    Evans AJ. Evans AJ. J R Soc Med. 1995 Mar;88(3):161P-165P. J R Soc Med. 1995. PMID: 7538588 Free PMC article. Review. No abstract available.
  • The relevance of pharmacokinetics in the development of biotechnology products.
    Toon S. Toon S. Eur J Drug Metab Pharmacokinet. 1996 Apr-Jun;21(2):93-103. doi: 10.1007/BF03190257. Eur J Drug Metab Pharmacokinet. 1996. PMID: 8839682 Review.

Publication types

LinkOut - more resources